PTC Therapeutics (PTCT) said late Monday it completed the acquisition of ST-920, a gene therapy for Fabry disease, a rare genetic disorder, from Sangamo Therapeutics.
A rolling biologics license application submission to the US Food and Drug Administration for accelerated approval of the therapy is expected to be completed in Q4, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.